Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





World-First Method for Rapid Isolation and Characterization of COVID-19 Variants

By LabMedica International staff writers
Posted on 01 Jun 2022

Researchers have developed a methodology that speeds up the process for isolating and characterizing the risks posed by COVID-19 variants of concern. More...

The methodology, which has been shared with the global scientific community through publication in Nature Microbiology, is highly cost-effective, automated, and can be used to measure the effectiveness of therapeutics and scaled to test thousands of samples.

The methodology, called R-20, was developed by researchers from the Kirby Institute at UNSW Sydney (Sydney, Australia) and used to analyze all major circulating viral variants in 2021 that were identified from patients in hotel quarantine. At the end of 2021, it was applied to Australia’s first Omicron samples. The researchers found that the vaccine-induced antibody response to Omicron was 15-20-fold weaker than to the original SARS-CoV-2 strain. The rapid analysis included details of how well the variant evades antibodies and how resilient it is. The results have been cited in Centers for Disease Control and Prevention (CDC) guidelines, World Health Organization (WHO) technical reports and by the Australian Technical Advisory group on Immunization (ATAGI) regarding the use of booster vaccinations.

In order to develop the methodology, the researchers took lessons learned from HIV to develop cells with receptors that viruses ‘like’. They looked at hundreds of different cells to identify ones that would allow the virus to replicate as quickly and effectively as possible. They termed these cells as the ‘canaries in the coal mine’ – because they effectively die in the process of telling the team what each variant is up to. They also allow the team to capture variants of the virus quicker than any other cell culture method, with sensitivities approaching that of a PCR swab test.

Using R-20, the researchers look at viral properties of variants to understand how sick the virus is likely to make the population, as well as how evasive it is to existing vaccines and treatments. Identifying this quickly is crucial to inform public health policies such as vaccination strategies, which therapeutics will still work and advice on mask use to mitigate spread of variants to vulnerable populations such as the elderly.

“What makes our R-20 approach unique is its speed and accuracy,” says Associate Professor Turville who developed the methodology. “The best way to quickly understand how a virus works is to genetically develop a cell with receptors that the virus likes. R-20 uses 'supercharged' cells that allow the virus to replicate four times faster than through any other techniques currently published in the scientific literature.”

Related Links:
UNSW Sydney 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Portable Electronic Pipette
Mini 96
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Beckman Coulter’s new launched BD-Tau RUO assay is available for use on the Access 2 Analyzer and DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Automated High Throughput Immunoassay Test to Advance Neurodegenerative Clinical Research

Alzheimer’s disease and other neurodegenerative disorders remain difficult to diagnose and monitor accurately due to limitations in existing biomarkers. Traditional tau and phosphorylated tau measurements... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.